Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions reports developments tied to its biotechnology platforms for producing precision-engineered recombinant proteins and enzymes. The company uses proprietary microbial expression systems, including C1 and Dapibus, to serve life sciences, food and nutrition, and industrial biotechnology applications through product sales, licensing, and partner commercialization.
Recurring news includes financial results, corporate update calls, commercial launches, distribution agreements, and development collaborations. Company updates have covered recombinant human albumin, animal-origin-free recombinant DNase I, transferrin, bovine alpha-lactalbumin, non-animal dairy enzymes, and broader portfolios for cell culture, molecular biology, nutrition, and bioindustrial markets.
Dyadic Applied BioSolutions (NASDAQ: DYAI) and Inzymes ApS announced planned 2026 commercialization of recombinant non-animal bovine chymosin for cheese production after completing final development activities.
Dyadic received a $200,000 milestone payment and remains eligible for royalties on future commercial sales; the global dairy processing enzyme market is estimated at $1.5–$2.0 billion annually.
Dyadic Applied BioSolutions (NASDAQ: DYAI) and Proliant Health & Biologicals announced the commercial launch of AlbuFree™ DX, a recombinant human albumin (rHA) product produced using Dyadic’s filamentous fungal expression technology on Feb 17, 2026.
Under the agreement, Dyadic will receive a share of profits from Proliant’s commercial sales. Proliant plans an expanded AlbuFree™ line later in 2026, including a formulation targeted for the cell culture market. Dyadic said the launch advances its strategy to convert licensed programs into recurring revenue and validates its microbial platform for scalable, animal-free protein production.
Dyadic (NASDAQ: DYAI) announced an expansion of its strategic collaboration with Fermbox Bio to broaden manufacture, commercialization, and dual-sourcing of Dyadic-developed animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets.
Key elements include Fermbox manufacturing multiple Dyadic-origin products at commercial scale, co-commercialization rights globally, inclusion of Fermbox-developed products into the joint portfolio, dual-sourcing via C1, Dapibus™ or alternative microbial systems, and a jointly managed, continuously updated product pipeline to accelerate development and shorten commercialization timelines.
Dyadic Applied BioSolutions (NASDAQ: DYAI) announced a commercial agreement with Opes Diagnostics Limited on Dec 15, 2025 to support the launch of Dyadic’s recombinant human transferrin, bovine transferrin, human FGF, and bovine FGF for serum-free cell culture media applications.
Opes will leverage existing commercial relationships to identify customers primarily in Europe, Israel, and Asia, while Dyadic retains direct-selling rights and can work with other partners. The collaboration aims to accelerate adoption across research, diagnostics, cultured meat, and biomanufacturing markets.
Dyadic (NASDAQ:DYAI) and BRIG BIO signed a Development & Commercialization Agreement on Dec 1, 2025 to jointly develop recombinant bovine alpha-lactalbumin for infant, clinical, active, and healthy-aging nutrition markets.
Under the deal, BRIG BIO will fully fund the development program and receive a global commercial license to Dyadic’s production strains in the Dapibus™ fungal expression system; Dyadic will receive milestone payments, long-term shared revenue participation, and co-marketing/sales rights. The partners target scalable, cost-effective, animal-free production to address a market projected from ~USD 760M (2025) to >USD 1.6B (2035).
Dyadic (NASDAQ: DYAI) reported Q3 2025 results and strategic progress on Nov 12, 2025, highlighting a commercial pivot and rebrand to Dyadic Applied BioSolutions. Key updates include a non-exclusive CRISPR/Cas9 license with ERS Genomics, first purchase orders in cell culture media and reagent segments, peer-reviewed validation of the C1 platform for SARS-CoV-2 spike production, and multiple program milestones across life sciences, nutrition, and bioindustrial markets.
Financially, Dyadic held $10.4M cash and equivalents as of Sept 30, 2025, completed an equity offering that raised net proceeds of $4.9M, reported Q3 revenue of $1.165M (down from $1.958M YoY), and a net loss of $1.976M (or $(0.06) per share).
Dyadic Applied BioSolutions (NASDAQ:DYAI) announced a commercial CRISPR/Cas9 license from ERS Genomics on Nov 10, 2025, granting access to ERS’ global patent portfolio to support genetic engineering across Dyadic’s C1 and Dapibus bioproduction platforms. The license is intended to accelerate strain engineering, pathway optimization, and integration of CRISPR gene editing into Dyadic’s internal pipeline and partner projects across life sciences, food & nutrition, and bio-industrial sectors.
ERS Genomics holds a portfolio of 100+ patents and reports 150+ licenses worldwide; financial terms of this agreement were not disclosed.
Dyadic Applied BioSolutions (Nasdaq: DYAI) announced it will report its financial results and host a corporate update conference call on Wednesday, November 12, 2025 at 5:00 p.m. ET.
The company notes a dial-in (Toll Free +1-877-407-0784; International +1-201-689-8560) and Conference ID 13751389, plus a live webcast and a replay available within 24 hours on the investor relations website. Investors may submit Q&A questions in advance via jlavalley@dyadic.com.
Dyadic Applied BioSolutions (NASDAQ: DYAI) reported commercial and product milestones in Q3 2025, including milestone payments and progress across life sciences and food & nutrition programs.
Key discrete items: a $500,000 productivity milestone for recombinant human albumin with payment expected in Q4 2025, and a $250,000 milestone received from the Inzymes partnership after Q3 2025 productivity improvements. Proliant has begun sampling albumin with a commercial launch targeted in late 2025–early 2026. Dyadic also reported sampling/production starts for transferrin, research-grade DNase I meeting activity and purity benchmarks, and a signed term sheet for non-animal human alpha-lactalbumin for infant nutrition. Several enzyme candidates are advancing with scale-up on track for late 2025.
Dyadic International (NASDAQ:DYAI), a biotechnology company specializing in precision engineered functional input proteins, has announced its participation in three upcoming conferences in September 2025.
The company's President & COO Joe Hazelton will present at the H.C. Wainwright Global Investment Conference (Sept 8-10), BioProcess International BPI East (Sept 15-18), and the Sidoti Small Cap Investor Event (Sept 17-18). Interested parties can schedule meetings with management by contacting jlavalley@dyadic.com.